About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Melanoma Clinical Trials in Ohio | 326 Studies

Clinical Trials MelanomaOhio

Melanoma Clinical Trials in Ohio

Find 326 clinical trials for melanoma near Ohio. Connect with research centers in your area.

All Melanoma trials nationwide All trials in Ohio

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 281-300 of 326 trials

CompletedImproving Sun-Protective Behaviors and Skin Self-Examinations Among African AmericansThis randomized clinical trial uses an educational brochure and online tutorial program to assess sun-protective behavior and skin self-examination among African Americans.NCT02417948·Cleveland, Ohio CompletedA Treatment Combination for Patients With Unresectable Stage III or Stage IV MelanomaThe objectives of this study are to compare the anti-tumor activity as measured by Progression Free Survival (PFS) and tolerability of Sorafenib in combination with Paclitaxel and…NCT00111007·Birmingham, Alabama and 65 others

PreviousPage 15 of 17Next

Melanoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

SuspendedKetogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney CancerThis phase I trial studies how well a ketogenic dietary intervention works to improve response to immunotherapy in patients with melanoma and kidney cancer that has spread from…NCT06391099·Columbus, Ohio

CompletedAnti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic MelanomaThis Phase II study is designed to evaluate the anti-tumor activity of three dose groups of SB-485232 (0.01, 0.1, and 1.0 mg/kg/day) administered intravenously as a single agent…NCT00107718·Los Angeles, California and 19 others

CompletedAn Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have SpreadThe purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and…NCT02658890·Tucson, Arizona and 46 others

RecruitingSYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryInternational registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool…NCT03452774·Birmingham, Alabama and 67 others

CompletedSafety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant MelanomaThe purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of GC1008, a human anti-transforming growth factor-beta (TGFβ) monoclonal…NCT00356460·Bethesda, Maryland and 5 others

CompletedA Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced MalignanciesThis is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and…NCT04772989·Los Angeles, California and 21 others

CompletedA Study of SEA-CD40 Given With Other Drugs in CancersThis trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer.NCT04993677·Springdale, Arkansas and 28 others

CompletedSubstudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)Substudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study.NCT04305041·Los Angeles, California and 35 others

CompletedStudy of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant MelanomaThe purpose of this study is to determine the safety, tolerability and dose limiting toxicities (DLTs) of VELCADE when administered in combination with interferon-alpha-2b…NCT01462773·Columbus, Ohio

CompletedPhase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous MelanomaThis is a Phase 2, multicenter, randomized, controlled, open-label trial of pimasertib versus dacarbazine aimed to confirm the activity of pimasertib in previously untreated…NCT01693068·Birmingham, Alabama and 100 others

CompletedA Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersThis is an open-label, multicenter, Phase 1/2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor…NCT02643303·Atlanta, Georgia and 6 others

CompletedMelanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)This study evaluates whether it is safe to administer a peptide vaccine made of 6MHP and a mutated neoantigen peptide (BRAF585-614-V600E) combined with adjuvants.NCT04364230·Cleveland, Ohio and 1 other

CompletedHepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to MelanomaRATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.NCT00324727·Santa Monica, California and 11 others

TerminatedTrial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant MelanomaThis phase 2 clinical trial randomizes patients with BRAF mutant melanoma to either (1) standard of care (SOC) - BRAF inhibitor vemurafenib in combination with MEK inhibitor…NCT01495988·Los Angeles, California and 13 others

CompletedStudy of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV MelanomaThe purpose of this clinical research study is to compare the best overall response rate (BORR)(as per modified WHO criteria) in patients with previously treated…NCT00289640·Tucson, Arizona and 61 others

CompletedA Companion Study for Patients Enrolled in Prior/Parent Ipilimumab StudiesThe purpose of this study was to evaluate the continued use of ipilimumab in patients who had reinduction at the time of disease progression or to continue maintenance treatment.NCT00162123·Tucson, Arizona and 57 others

CompletedA Study of Intratumoral IMO-2125 in Patients With Refractory Solid TumorsThis is a Phase 1b study that incorporates dose expansion cohorts to further evaluate promising clinical or biological activity.NCT03052205·Scottsdale, Arizona and 11 others

RecruitingPromoting Immunotherapy Efficacy With Low-Dose Liver RTThe purpose of this study is to see if adding Low-Dose Liver Radiation (LD-LRT) improves progression free survival (PFS).NCT07225036·Cincinnati, Ohio

Other Conditions in Ohio

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Leukemia Lymphoma